The answer to this with current trends been seen through state department of health, CDC, WHO, NIH, FDA is that this is an extremely high possibility. A classical example is seen with NG in which currently there is only one dual therapy that currently works with some strains already showing resistance to one of the medications used. NG, according to CDC, is show a trend of mortality that will surpass cancer by an extremely high fold in the year 2050, along with some other superbugs. A contributing factor to this is that the production of new antibiotics and antimicrobials has been at a standstill due to major companies not seeking a profit from the market and will the current issues of trying to find a new source that contains no resistance to any to the super bugs (this is different then using changes in chemical subgroups of base component chemical structures in chemical medicinal chemistry). Through potentially increased funding from the government, grants, etc and through the strict enforcement of stewardship programs in l aspects of healthcare, and medication prescription the battle on superbugs can potentially be slowed down a bit. Now this doesn't include emerging and remerging pathogens of high concern esp in the high risk groups such as pediatrics.
